Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • The AASLD/IDSA guidelines recommend that children with chronic HCV infection who are older than 3 years of age should receive treatment with DAA regimens, if available for the child’s age group[AASLD-IDSA HCV]
  • Glecaprevir/pibrentasvir is the first choice for adolescent treatment of HCV and is approved for adolescents aged 12-17 years with any HCV genotype
  • Ledipasvir/sofosbuvir and sofosbuvir plus ribavirin are approved by the FDA for the treatment of HCV infection in patients 3 years of age and older

    Action required

    Keywords: Hepatitis C, Hepatitis C-Special Populations, Hepatitis C-Sustained Virologic Response, Hepatitis C-Treatment

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.